Breast cancer vaccine shows promising results in phase 1 clinical trials

A new breast cancer vaccine has completed phase 1 clinical trials, showing promising results. Developed by Anixa Biosciences in collaboration with Cleveland Clinic, the vaccine aims to prevent breast cancer by targeting a specific



protein. 

The trial involved 35 high-risk women, with over 75% developing a strong immune response. Phase 2 trials are set to begin in 2026, marking a significant step towards potentially preventing breast cancer.